Unmet needs and challenges in gastric cancer: The way forward

Cancer Treatment Reviews

Volumn 40, Issue 6, 2014, Pages 692-700

  Lordick, Florian ^a   Allum, William ^b   Carneiro, Fátima ^c   Mitry, Emmanuel ^d   Tabernero, Josep ^e   Tan, Patrick ^f   Van Cutsem, Eric ^g   Van de Velde, Cornelis ^h   Cervantes, Andrés ⁱ  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c University of Porto   (Portugal)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Drug development; Gastric cancer; Heterogeneity; Pathogenesis; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; LAPATINIB; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RAMUCIRUMAB; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; TRASTUZUMAB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; EUROPE; GASTRECTOMY; HEALTH SERVICE; HUMAN; MEDICAL AUDIT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; STOMACH CANCER;

DRUG DEVELOPMENT; GASTRIC CANCER; HETEROGENEITY; PATHOGENESIS; TREATMENT;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELIVERY OF HEALTH CARE; DRUG DESIGN; EUROPE; GASTRECTOMY; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; QUALITY CONTROL; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; STOMACH NEOPLASMS;

EID: 84899901507     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.03.002     Document Type: Review

References (105)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.10. Lyon, France: International Agency for Research on Cancer. 2010; Available from: < http://www.globocan.iarc.fr.
2. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures 2007. American Cancer Society. Available from:. http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures%202007rev2p.pdf.
3. Gastric cancer in Europe. Br J Surg 2008, 95:406-408. European Union Network of Excellence (EUNE) for Gastric Cancer Steering Group.
4. De Angelis R., Sant M., Coleman M.P., et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:23-34.
5. Lauwers G.Y., Carneiro F., Graham D.Y., et al. Gastric carcinoma. WHO classification of tumours of the digestive system 2010, 48-58. IARC, Lyon. 4th ed. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
6. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
7. Yamashita K., Sakuramoto S., Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011, 41:24-38.
8. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740.
9. Argent R.H., Thomas R.J., Aviles-Jimenez F., et al. Toxigenic Helicobacter pylori infection precedes gastric hypochlorhydria in cancer relatives, and H. pylori virulence evolves in these families. Clin Cancer Res 2008, 14:2227-2235.
10. Figueiredo C., Machado J.C., Pharoah P., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002, 94:1680-1687.
11. Machado J.C., Figueiredo C., Canedo P., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003, 125:364-371.
12. Ohata H., Kitauchi S., Yoshimura N., et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004, 109:138-143.
13. Hudler P. Genetic aspects of gastric cancer instability. Scientific World J 2012, 2012:761909.
14. Iizasa H., Nanbo A., Nishikawa J., Jinushi M., Yoshiyama H. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses 2012, 4:3420-3439.
15. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
16. Caldas C., Carneiro F., Lynch H.T., et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999, 36:873-880.
17. Carneiro F., Charlton A., Huntsman D.G. Hereditary diffuse gastric cancer. WHO classification of tumours of the digestive system 2010, 59-63. IARC, Lyon. 4th ed. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
18. Worthley D.L., Phillips K.D., Wayte N., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012, 61:774-779.
19. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trial. Lancet 2010, 376:687-697.
20. Jørgensen J.T., Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer 2012, 3:137-144.
21. Kim M.A., Lee H.S., Lee H.E., Jeon Y.K., Yang H.K., Kim W.H. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008, 52:738-746.
22. Barber M., Fitzgerald R.C., Caldas C. Familial gastric cancer - aetiology and pathogenesis. Best Pract Res Clin Gastroenterol 2006, 20:721-734.
23. Fitzgerald R.C., Hardwick R., Huntsman D., et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444.
24. Oliveira C., Pinheiro H., Figueiredo J., Seruca R., Carneiro F. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci 2013, 116:337-359.
25. Majewski I.J., Kluijt I., Cats A., et al. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013, 229:621-629.
26. Moehler M., Al-Batran S.E., Andus T., et al. German S3-guideline. Diagnosis and treatment of esophagogastric cancer. Z Gastroenterol 2011, 49:461-531. [Article in German].
27. National Comprehensive Cancer Network. Gastric cancer. Version 2, 2012. Available from:. http://www.nccn.com/patient-guidelines.html.
28. Zang Z.J., Cutcutache I., Poon S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012, 44:570-574.
29. Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684.
30. Zouridis H., Deng N., Ivanova T., et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 2012, 4(156ra140):156.
31. Lei Z., Tan I.B., Das K., et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013, 145:554-565.
32. Waddell T., Verheij M., Allum W., Cunningham D., Cervantes A., Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl. 6):vi57-vi63.
33. Scottish Intercollegiate Guidelines Network. Management of oesophageal and gastric cancer. A national clinical guideline. Available from:. http://www.sign.ac.uk/pdf/sign87.pdf.
34. Meyer H.J., Hölscher A.H., Lordick F., et al. Current S3 guidelines on surgical treatment of gastric carcinoma. Chirurg 2012, 83:31-37.
35. Lutz M.P., Zalcberg J.R., Ducreux M., et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012, 48:2941-2953.
36. Allum W.H., Blazeby J.M., Griffin S.M., et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011, 60:1449-1472.
37. Japanese Gastric Cancer Association Japanese gastric cancer guidelines 2010 (ver. 3). Gastric Cancer 2011, 14:113-123.
38. Jatzko G.R., Lisborg P.H., Denk H., Klimpfinger M., Stettner H.M. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer 1995, 76:1302-1312.
39. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999, 79:1522-1530.
40. Degiuli M., Sasako M., Ponti A. Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010, 97:643-649.
41. Songun I., Putter H., Kranenbarg E.M., Sasako M., van de Velde C.J. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11:439-449.
42. Kim H.H., Hyung W.J., Cho G.S., et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report - a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010, 251:417-420.
43. Katai H., Sasako M., Fukuda H., et al. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial. Gastric cancer 2010, 13:238-244.
44. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med 2006, 355:11-20.
45. Boige V., Pignon J., Saint-Aubert B., et al. FNLCC ACCORD 07-FFCD 9703 trial - final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE). Proc Am Soc Clin Oncol 2007, 25(18S):4510.
46. Schuhmacher C., Gretschel S., Lordick F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010, 28:5210-5218.
47. Chua Y.J., Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol 2007, 14:2687-2690.
48. Cunningham D., Rao S., Starling N., et al. Randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 2006, 24(Suppl. 18). abstr. LBA4017.
49. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
50. Lordick F., Stein H.J., Peschel C., Siewert J.R. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004, 91:540-551.
51. Paoletti X., Oba K., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729-1737. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.
52. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
53. Van Cutsem E., Dicato M., Geva R., et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12thESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011, 22(Suppl. 5):v1-v9.
54. Rivera F., Grávalos C., García-Carbonero R. SEOM (Spanish Society of Clinical Oncology).SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol 2012, 14:528-535.
55. Cervantes A., Roda D., Tarazona N., Rosello S., Perez-Fidalgo J.A. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013, 39:60-67.
56. Lordick F., Lorenzen S., Yamada Y., Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer 2013, Sep 19. [Epub ahead of print].
57. Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010, 3:CD004064.
58. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24:4991-4997.
59. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
60. Starling N., Rao S., Cunningham D., et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009, 27:3786-3793.
61. Okines A.F., Norman A.R., McCloud P., et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009, 20:1529-1534.
62. Dank M., Zaluski J., Barone C., et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008, 19:1450-1457.
63. Rüschoff J., Hanna W., Bilous M., et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012, 25:637-650.
64. Waddell T., Chau I., Cunningham D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14:481-489.
65. Lordick F., Kang Y.K., Chung H.C., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14:490-499.
66. Bang Y.-J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 2012, 30(Suppl. 34). abstr. 11.
67. Okines A.F., Langley R.E., Thompson L.C., et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol 2013, 24:702-709.
68. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29:3968-3976.
69. Fuchs C.S., Tomasek J., Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383:31-39. for the REGARD Trial Investigators.
70. Lee J.L., Ryu M.H., Chang H.M., et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008, 61:631-637.
71. Assersohn L., Brown G., Cunningham D., et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004, 15:64-69.
72. Chun J.H., Kim H.K., Lee J.S., et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004, 34:8-13.
73. Sym S.J., Chang H.M., Kang H.J., et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol 2008, 63:1-8.
74. Thuss-Patience P.C., Kretzschmar A., Bichev D., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011, 47:2306-2314.
75. Kang J.H., Lee S.I., Lim do H., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012, 30:1513-1518.
76. Ford H.E., Marshall A., Bridgewater J.A., et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014, 15:78-86.
77. Hironaka S., Ueda S., Yasui H., et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013, Nov 4. [Epub ahead of print].
78. Wilke H., Van Cutsem E., Oh S.C., et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 2014, 32(Suppl. 3). abstr. LBA7.
79. Shah M.A., Khanin R., Tang L., et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011, 17:2693-2701.
80. Ohtsu A., Ajani J.A., Bai Y.X., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013, 31:3935-3943.
81. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
82. Kruser T.J., Wheeler D.L. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010, 316:1083-1100.
83. Kim S.E., Shim K.N., Jung S.A., Yoo K., Lee J.H. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009, 3:88-94.
84. Lieto E., Ferraraccio F., Orditura M., et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15:69-79.
85. Shah M., Van Cutsem E., Kang Y.-K., et al. Survival analysis according to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. J Clin Oncol 2012, 30(Suppl. 4). abstr. 5.
86. Van Cutsem E., de Haas S., Kang Y.K., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012, 30:2119-2127.
87. Xu D.Z., Geng Q.R., Tian Y., et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 2010, 10:536.
88. Yu G., Wang J., Chen Y., et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829.
89. Taguchi F., Kodera Y., Katanasaka Y., Yanagihara K., Tamura T., Koizumi F. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 2011, 29:1198-1205.
90. Jaeger-Lansky A., Cejka D., Ying L., et al. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol Ther 2010, 9:919-927.
91. Kawakami H., Okamoto I., Arao T., et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 2013, 4:9-17.
92. Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol 2009, 36(2 Suppl. 1):S52-S58.
93. Iveson T. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012, 30(Suppl.). abstr. 4005.
94. Oliner K.S., Tang R., Anderson A., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012, 30(Suppl.). abstr. 4005.
95. Ajani J.A., Mansfield P.F., Crane C.H., et al. Paclitaxelbased chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23:1237-1244.
96. Ajani J.A., Winter K., Okawara G.S., et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006, 24:3953-3958.
97. Kollmannsberger C., Budach W., Stahl M., et al. Adjuvant chemoradiation using 5-fluorouracil/ folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 2005, 16:1326-1333.
98. Lordick F. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res 2012, 196:201-211.
99. Becker K., Langer R., Reim D., et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011, 253:934-939.
100. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8:797-805.
101. Lordick F., Ruers T., Aust D.E., et al. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 2008, 44:1807-1819.
102. Krijnen P., den Dulk M. Meershoek-Klein Kranenbarg E, Jansen-Landheer ML, van de Velde CJ. Improved survival after resectable non-cardiagastric cancer in The Netherlands: the importance of surgical training and quality control. Eur J Surg Oncol 2009, 35:715-720.
103. Dikken J.L., van Sandick J.W., Allum W.H., et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013, 100:83-94.
104. de Steur W.O., Henneman D., Allum W.H., et al. Common data items in seven European oesophagogastric cancer surgery registries: towards a European Upper GI Cancer Audit (EURECCA Upper GI). Eur J Surg Oncol 2014, 40:325-329.
105. European Registration of Cancer Care, 2013. Available from:. http://www.canceraudit.eu/index.php?paginaid=5.